ImageneBio Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMA research report →
Range $1.33 – $1.33
Price Chart
About the company
ImageneBio, Inc. , a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
- CEO
- Kristin Yarema
- IPO
- 1998
- Employees
- 18
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on IMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.88M
- P/E
- -0.88
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- 0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.99%
- ROIC
- -39.76%
Latest fiscal year · YoY change
- Revenue
- $800.00K-77.1%
- Gross Profit
- $-233,000-111.8%
- Op Income
- $-48,451,000
- Net Income
- $-45,349,000-24.0%
- EPS
- $-9.64+76.2%
- OCF Growth
- -4.0%
- FCF Growth
- -4.0%
- 52W High
- $9.10
- 52W Low
- $3.94
- 50D MA
- $5.25
- 200D MA
- $5.85
- Beta
- 0.74
- RSI (14)
- 35
- Avg Volume
- 12.78K
No earnings-call transcripts are available for IMA yet.
- Free Float
- 64.5%
- Shares Outstanding
- 11.28M
- Float Shares
- 7.28M
of shares held by institutions
39 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 1.11M | 0 |
| Blue Owl Capital Holdings LP | 917.69K | ▼ 41.65K |
| Orbimed Advisors LLC | 909.27K | ▲ 530.71K |
| Cable Car Capital LLC | 781.60K | ▲ 26.85K |
| Omega Fund Management, LLC | 455.36K | 0 |
| Rtw Investments, LP | 334.44K | 0 |
| Vanguard Capital Management LLC | 320.52K | ▼ 4.64K |
| Trails Edge Capital Partners, LP | 282.00K | ▲ 282.00K |
| Vanguard Group Inc | 238.00K | ▲ 4.64K |
| Bml Capital Management, LLC | 200.73K | 0 |
| Monashee Investment Management LLC | 192.34K | ▲ 192.34K |
| Blackrock, Inc. | 135.09K | ▲ 5.88K |
Held by 25 ETFs
Biggest fund positions in IMA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Yarema Kristin | other | 254,800 |
| Aug 14, 26 | Yarema Kristin | other | 250,000 |
| Aug 14, 26 | Yarema Kristin | other | 137,200 |
| Aug 14, 26 | Grant-Huerta Yanina | other | 39,000 |
| Aug 14, 26 | Grant-Huerta Yanina | other | 65,000 |
| Aug 14, 26 | Grant-Huerta Yanina | other | 56,000 |
| Jul 20, 26 | Grant-Huerta Yanina | other | 0 |
| Jul 25, 26 | Yarema Kristin | other | 115,129 |
| Jul 25, 26 | Yarema Kristin | other | 38,376 |
| Jul 25, 26 | Yarema Kristin | other | 38,376 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMA coverage
Recent articles, reports, and earnings notes.
No research on IMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMA report →ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey
defenseworld.net · Oct 6
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
globenewswire.com · Sep 8
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 17
ImageneBio Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 5
ImageneBio Appoints Matt Robbins as General Counsel
globenewswire.com · Jul 7
Independent Medical Alliance Launches IMA Academy, Expanding Access to Expert-Led, CME-Accredited Medical Education
businesswire.com · Jun 11
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
globenewswire.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.